Cost-effectiveness of a gene sequencing test for Alzheimer’s disease in Ontario

Economic evaluation of next‐generation sequencing techniques in diagnosis of genetic disorders: A systematic review

“…Seven studies were performed on the lifetime time horizon 15–18,24,40,47 . In addition, a number of studies were conducted in the time horizons of 1 year ( n = 5), 2,23,27,29,31 2 years ( n = 1), 45 3 years ( n = 3), 30,32,44 5 years ( n = 1), 26 18 years ( n = 1), 21 20 years ( n = 1), 37 25 years ( n = 2), 20,48 30 years ( n = 1), 28 437 days ( n = 1), 39 and 1315 days ( n = 1) 14 . Thirteen studies were conducted based on modeling 14,16,18–21,24–29,31,32,35,40,45 .…”

“…According to the results of this study, ONDRISeq saves $54 per patient compared with OOC testing and results in a small QALY gain in the base case (0.0014 per patient). ONDRISeq is expected to reduce costs for the health care system 48 …”

“…Most studies were performed in Australia (n = 13). 21,23,25,27,28,33,[36][37][38][39]42,44,46 In addition, nine studies were done in the United States, 17,18,20,24,26,31,35,40,47 five studies in Canada, 22,30,32,45,48 and three studies in England 2,29,40 ; also, one study was conducted in the Netherlands, 43 Norway, 15 China, 19 Thailand, 34 Israel, 41 Iran, 16 and Finland. 14 Eleven studies were done from the payer perspective.…”

“…As shown in Table S2, 19 studies received scores above 75, falling into the category of high-quality studies. 2,15,17,18,20,21,24,[26][27][28][29]32,33,42,43,[46][47][48] Fifteen studies scored between 51-74 (medium quality). 14,19,22,25,30,[34][35][36][37]39,41,44,45 All studies did not provide a justification for using the study perspective.…”

“…14 Eleven studies were done from the payer perspective. 2,18,19,30,31,36,39,40,45,48 In addition, from the health system, provider and social perspectives, nine studies, 15,16,20,21,[26][27][28][29]43 three studies, 14,22,38 and five studies 20,40,41,45,47 were performed, respectively.…”